| pubmed-article:8635066 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C0004997 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C1101536 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:8635066 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:8635066 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8635066 | pubmed:dateCreated | 1996-7-9 | lld:pubmed |
| pubmed-article:8635066 | pubmed:abstractText | Previous studies have established that soluble interleukin-2 receptor alpha (sIL-2R alpha) levels are elevated in ascites and sera from individuals with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] Stage III/IV). This study was undertaken to evaluate sIL-2R alpha levels in individuals with benign ovarian neoplasms and early stage ovarian cancer (FIGO Stage I/II). Comparison with CA 125 levels was performed to assess screening potential. | lld:pubmed |
| pubmed-article:8635066 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8635066 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635066 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8635066 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635066 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635066 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635066 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8635066 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8635066 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:NelsonD LDL | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:BartT HTH | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:BerchuckAA | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:MillsG BGB | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:JacobsI JIJ | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:RubinL ALA | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:KurmanC CCC | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:HurteauJ AJA | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:WoolasR PRP | lld:pubmed |
| pubmed-article:8635066 | pubmed:author | pubmed-author:OramD CDC | lld:pubmed |
| pubmed-article:8635066 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8635066 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8635066 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:8635066 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8635066 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8635066 | pubmed:pagination | 1615-20 | lld:pubmed |
| pubmed-article:8635066 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:meshHeading | pubmed-meshheading:8635066-... | lld:pubmed |
| pubmed-article:8635066 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8635066 | pubmed:articleTitle | Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:8635066 | pubmed:affiliation | Division of Oncology Research, Toronto General Hospital, Ontario, Canada. | lld:pubmed |
| pubmed-article:8635066 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8635066 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8635066 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8635066 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8635066 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
